{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:01:40Z","timestamp":1793073700124,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We evaluated comprehension and application of the 2015 neuromyelitis optica spectrum disorder (NMOSD) criteria core elements by neurologists in Latin America (LATAM) who routinely diagnose and care for NMOSD patients by (i) identifying typical\/suggestive NMOSD syndromes, (ii) detecting typical MRI NMOSD lesions and meeting MRI dissemination in space (DIS) criteria, and (iii) evaluating historical symptoms suggestive of NMOSD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted an anonymous, voluntary, self-administered web- and case-based survey cross-sectional study from October 2023 to January 2024 of neurologists identified through the LACTRIMS database. Questions were presented first through iterative clinical cases or imaging, followed by questions directly evaluating comprehension of definitions. \u201cCorrect\u201d responses were based on the 2015 criteria and adjudicated by the consensus of the experts leading the project.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 106 neurologists (60.3% female; mean age: 46.6 \u00b1 12.5 years) were included. Between 10.4% and 49.1% of neurologists inaccurately identified clinical or paraclinical aspects for DIS and 32.1% accurately identified the three non-cardinal (brainstem, diencephalic, and cerebral) syndromes for seronegative patients. Between 35.8% and 64.1% of neurologists identified the \u201coptimal timing\u201d of AQP4-IgG testing (e.g., during an attack or before receiving immunosuppressant treatments, among others); 56.6% considered live cell-based assay as the gold standard method for serological testing. Most neurologists accurately identified typical NMOSD MRI lesions, but periventricular, juxtacortical\/cortical, fluffy infratentorial, corticospinal tract, and hypothalamic lesions were frequently misidentified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Clinical scenarios were identified where the 2015 NMOSD criteria were susceptible to misinterpretation and misapplication by expert neurologists in LATAM. Implementing collaborative educational initiatives could improve NMOSD diagnosis and raise patient care standards.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1515481","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:11:04Z","timestamp":1734066664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Application and interpretation of core elements of the 2015 NMOSD diagnostic criteria in routine clinical practice"],"prefix":"10.3389","volume":"15","author":[{"given":"Edgar","family":"Carnero Contentti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Yeaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflamm"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/jon.13137","article-title":"MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease","volume":"33","author":"Carnero Contentti","year":"2023","journal-title":"J Neuroimaging"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00148-5","article-title":"Differential diagnosis of suspected multiple sclerosis: an updated consensus approach","volume":"22","author":"Solomon","year":"2023","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15983","article-title":"Non-demyelinating disorders mimicking and misdiagnosed as NMOSD: a literature review","volume":"30","author":"Zara","year":"2023","journal-title":"Eur J Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308984","article-title":"Overlapping CNS inflammatory diseases: differentiating features of NMO and MS","volume":"86","author":"Jury\u0144czyk","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25411","article-title":"Brain and cord imaging features in neuromyelitis optica spectrum disorders","volume":"85","author":"Cacciaguerra","year":"2019","journal-title":"Ann Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2021.1949686","article-title":"Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America","volume":"43","author":"Rojas","year":"2021","journal-title":"Neurol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221136259","article-title":"Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors","volume":"29","author":"Carnero Contentti","year":"2023","journal-title":"Mult Scler"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.01.001","article-title":"Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients","volume":"20","author":"Carnero Contentti","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"44:102310","DOI":"10.1016\/j.msard.2020.102310","article-title":"Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey","author":"Ricardo","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12070885","article-title":"NMOSD-diagnostic dilemmas leading towards final diagnosis","volume":"12","author":"Szewczyk","year":"2022","journal-title":"Brain Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104498","article-title":"Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder","volume":"70","author":"Smith","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2015.106","article-title":"Most Scottish neurologists do not apply the 2010 McDonald criteria when diagnosing multiple sclerosis","volume":"45","author":"Lumley","year":"2015","journal-title":"J R Coll Phys Edinb"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211048401","article-title":"Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States","volume":"28","author":"Solomon","year":"2022","journal-title":"Mult Scler"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520910496","article-title":"Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria","volume":"27","author":"Solomon","year":"2021","journal-title":"Mult Scler"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103356","article-title":"AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder","volume":"57","author":"Marignier","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7952-8","article-title":"Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO\/MS overlap syndromes","volume":"263","author":"Jury\u0144czyk","year":"2016","journal-title":"J Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231179108","article-title":"Rectifying global inequities in neuromyelitis optica diagnosis and treatment","volume":"29","author":"Mateen","year":"2023","journal-title":"Mult Scler"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231190248","article-title":"Rectifying global inequities in neuromyelitis optica diagnosis and treatment: A critical view from Latin America","volume":"29","author":"Carnero Contentti","year":"2023","journal-title":"Mult Scler"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1515481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:11:07Z","timestamp":1734066667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1515481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2024.1515481"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1515481","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"article-number":"1515481"}}